These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 16959793)

  • 1. Beta-synuclein modulates alpha-synuclein neurotoxicity by reducing alpha-synuclein protein expression.
    Fan Y; Limprasert P; Murray IV; Smith AC; Lee VM; Trojanowski JQ; Sopher BL; La Spada AR
    Hum Mol Genet; 2006 Oct; 15(20):3002-11. PubMed ID: 16959793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. alpha-Synuclein is colocalized with 14-3-3 and synphilin-1 in A53T transgenic mice.
    Shirakashi Y; Kawamoto Y; Tomimoto H; Takahashi R; Ihara M
    Acta Neuropathol; 2006 Dec; 112(6):681-9. PubMed ID: 16957925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery.
    Lee VM; Trojanowski JQ
    Neuron; 2006 Oct; 52(1):33-8. PubMed ID: 17015225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant alpha-synuclein-induced toxicity.
    Smith WW; Jiang H; Pei Z; Tanaka Y; Morita H; Sawa A; Dawson VL; Dawson TM; Ross CA
    Hum Mol Genet; 2005 Dec; 14(24):3801-11. PubMed ID: 16239241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
    Olanow CW; Brundin P
    Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Wild-type and mutant alpha-synuclein induce a multi-component gene expression profile consistent with shared pathophysiology in different transgenic mouse models of PD.
    Miller RM; Kiser GL; Kaysser-Kranich T; Casaceli C; Colla E; Lee MK; Palaniappan C; Federoff HJ
    Exp Neurol; 2007 Mar; 204(1):421-32. PubMed ID: 17254569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease.
    Orimo S; Uchihara T; Nakamura A; Mori F; Kakita A; Wakabayashi K; Takahashi H
    Brain; 2008 Mar; 131(Pt 3):642-50. PubMed ID: 18079166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Agrin binds alpha-synuclein and modulates alpha-synuclein fibrillation.
    Liu IH; Uversky VN; Munishkina LA; Fink AL; Halfter W; Cole GJ
    Glycobiology; 2005 Dec; 15(12):1320-31. PubMed ID: 16037493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exacerbated synucleinopathy in mice expressing A53T SNCA on a Snca null background.
    Cabin DE; Gispert-Sanchez S; Murphy D; Auburger G; Myers RR; Nussbaum RL
    Neurobiol Aging; 2005 Jan; 26(1):25-35. PubMed ID: 15585343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beta-synuclein inhibits formation of alpha-synuclein protofibrils: a possible therapeutic strategy against Parkinson's disease.
    Park JY; Lansbury PT
    Biochemistry; 2003 Apr; 42(13):3696-700. PubMed ID: 12667059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in adult olfactory bulb neurogenesis in mice expressing the A30P mutant form of alpha-synuclein.
    Marxreiter F; Nuber S; Kandasamy M; Klucken J; Aigner R; Burgmayer R; Couillard-Despres S; Riess O; Winkler J; Winner B
    Eur J Neurosci; 2009 Mar; 29(5):879-90. PubMed ID: 19291219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitochondrial associated metabolic proteins are selectively oxidized in A30P alpha-synuclein transgenic mice--a model of familial Parkinson's disease.
    Poon HF; Frasier M; Shreve N; Calabrese V; Wolozin B; Butterfield DA
    Neurobiol Dis; 2005 Apr; 18(3):492-8. PubMed ID: 15755676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A molecular pathway of neurodegeneration linking alpha-synuclein to ApoE and Abeta peptides.
    Gallardo G; Schlüter OM; Südhof TC
    Nat Neurosci; 2008 Mar; 11(3):301-8. PubMed ID: 18297066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Controlling the mass action of alpha-synuclein in Parkinson's disease.
    Kim C; Lee SJ
    J Neurochem; 2008 Oct; 107(2):303-16. PubMed ID: 18691382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity.
    Kontopoulos E; Parvin JD; Feany MB
    Hum Mol Genet; 2006 Oct; 15(20):3012-23. PubMed ID: 16959795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alpha- and beta-synuclein expression in Parkinson disease with and without dementia.
    Beyer K; Ispierto L; Latorre P; Tolosa E; Ariza A
    J Neurol Sci; 2011 Nov; 310(1-2):112-7. PubMed ID: 21683963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parkinson's disease genetic mutations increase cell susceptibility to stress: mutant alpha-synuclein enhances H2O2- and Sin-1-induced cell death.
    Jiang H; Wu YC; Nakamura M; Liang Y; Tanaka Y; Holmes S; Dawson VL; Dawson TM; Ross CA; Smith WW
    Neurobiol Aging; 2007 Nov; 28(11):1709-17. PubMed ID: 16978743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synucleins and their relationship to Parkinson's disease.
    von Bohlen Und Halbach O
    Cell Tissue Res; 2004 Oct; 318(1):163-74. PubMed ID: 15503152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of a alpha-synuclein-based rat model of Parkinson's disease.
    Recchia A; Rota D; Debetto P; Peroni D; Guidolin D; Negro A; Skaper SD; Giusti P
    Neurobiol Dis; 2008 Apr; 30(1):8-18. PubMed ID: 18313315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Controlling aggregation propensity in A53T mutant of alpha-synuclein causing Parkinson's disease.
    Kumar S; Sarkar A; Sundar D
    Biochem Biophys Res Commun; 2009 Sep; 387(2):305-9. PubMed ID: 19580781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.